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Abstract
Background: Pediatric acute-liver-failure due to acetaminophen (APAP) administration at therapeutic dosage is rare,
while viral infections and metabolic defects are the prevalent causes. Yet, as acetaminophen is routinely used in
febrile illnesses, it may be mistakenly held responsible for the acute liver damage.
Case presentation: An 11 month old boy had been on acetaminophen for 10 days (total dose 720 mg = 72 mg/kg)
when he developed acute-liver-failure with encephalopathy. As he rapidly improved on N-acetylcysteine (NAC)
infusion, it was concluded that chronic acetaminophen administration in an infant had lead to acute-liver-failure even
at therapeutic doses, that N-acetylcysteine infusion had been life-saving and should be immediately started in similar
circumstances. The child, however, had two further episodes of acute liver damage over a 34-month period, without
having been given acetaminophen, as the parents carefully avoided using it. His clinical, laboratory and radiological
findings between the acute episodes were unremarkable. His features and skeletal surveys were not suggestive of a
syndromic condition. He then went on to suffer another episode of acute-liver-failure with multi-organ failure,
necessitating an urgent liver transplant. All efforts to come to a diagnosis for the causes of his recurrent episodes of
liver failure had been unsuccessful, until a biallelic mutation in the NBAS gene was reported to be associated with
recurrent acute-liver-failure in children. The boy’s DNA analysis revealed compound heterozygous pathogenic
mutations in the NBAS gene. Liver failure episodes in these patients are triggered and worsened by fever, most
likely due to thermal susceptibility of hepatocytes, hence APAP, rather than being a culprit, is part of the
supportive treatment.
Conclusions: We suggest that, in acute-liver-failure with a history of acetaminophen exposure at therapeutic
dosage, clinicians should not be contented with administering NAC, but should consider an alternative etiology,
above all if the episodes are recurrent, and actively start supportive and antipyretic treatment while seeking the
advice of a specialist unit.
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Background
Acute liver failure (ALF) is a rare syndrome, characterized
by rapid onset of severe hepatic dysfunction and hepato-
cellular damage in the absence of pre-existent liver disease
[1]. In children, it is a devastating illness that still carries a
high risk of mortality. In up to 50% of cases a cause can-
not be found despite thorough investigation [2].
The syndrome may have diverse etiologies that mani-
fest wide geographic and age differences. Etiology is an
important factor in determining outcome. Patients with
acute acetaminophen (N-acetyl-p-aminophenol = APAP)
toxicity would be expected to have a relatively good
prognosis, given the known pathobiology and the avail-
ability of a treatment for this condition. Yet, individual
patients with APAP-induced ALF may die [3].
APAP is a widely-used medication. It is available with-
out prescription and is a trusted remedy in most home
medicine cabinets. APAP is considered safe when taken
at the recommended dose (10–15 mg/kg) and frequency
(fewer than 5 doses/day) for a total recommended daily
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dose of 75 mg/kg per day [4]. Yet APAP toxicity is the
commonest cause for liver failure and liver transplant-
ation in the Western world [5].
Pediatric acute-liver-failure due to chronic acetamino-
phen administration at therapeutic dosage is rare [6]. In
one instance, such association was mistakenly reported.
Case Presentation
The case of an 11-month-old boy (10 kg), now 7, was pub-
lished in 2011 [7]. He had presented in discrete general
health with a 10-day history of fever and vomiting. Investi-
gations showed significantly elevated liver enzymes (LFT)
(AST 11,735 IU/L [normal range: < 41 IU/L], ALT
6611 IU/L [normal range: < 41 IU/L]) and γGT 286 IU/L
[normal range: < 71 IU/L]), normal total serum bilirubin
and normal clotting. His LFT values remained unchanged
the following day, while ammonium concentration was
high (266 μg/dL [normal range: < 125 μg/dL]), total
bilirubin increased significantly (2.18 mg/dL, direct
1.51 mg/dL), the international normalized ratio (INR) rose
to 2.07 [normal range: < 1.20] and did not respond to par-
enteral vitamin K administration. He became lethargic
with a normal electroencephalogram (EEG) and the
clinical picture suggested acute-liver-failure (ALF).
His pediatrician had been treating his fever with
APAP suppositories at 125 mg (12.5 mg/kg) every 6 h
for 3 days, followed by oral administration at 120 mg
(12 mg/kg) every 4 h for 7 days, for a total dose of
720 mg (72 mg/kg) over 10 days. His serum APAP
concentration 9 h after the last dose was 7.2 mg/mL
(reference range: 10.0–30.0 mg/mL). He was given N-
acetylcysteine (NAC) infusion at a dose of 150 mg/kg
in 5% dextrose in 90 min and then 150 mg/kg/day with
rapid improvement of his LFT on the first day and
normalization of the INR within 5 days. Five and 10
months later, two further febrile episodes lasting less
than 24 h with only a slight ALT alteration (102 and
65 IU/L respectively), were not treated with APAP. An
exhaustive etiological screening for pediatric ALF was
inconclusive and as the child had remained in good
health for 12 months, the clinicians reporting his case
presumed that his ALF had been induced by chronic
APAP administration at therapeutic dosage and that
NAC treatment had been “life-saving” [1, 4, 5].
Twenty-three months after his first ALF episode,
when he was 34 months old, he re-presented with leth-
argy after 6 h of fever and recurrent vomiting. There
was a marked alteration in AST (15,487 IU/L), ALT
(10,088 IU/L), normal γGT (35 IU/L) and total biliru-
bin, an increased INR (3.27) and a high ammonium
concentration (453 μg/dL). EEG showed diffuse cere-
bral suffering. Supportive treatment and NAC infusion
were commenced immediately, but the encephalopathy
and liver dysfunction worsened dramatically. Within
36 h the INR rose to 5.06, AST and ALT were 20,070
and 12,830 IU/L respectively, LDH was 22,392 IU/L
and ammonium 479 μg/dL. He was listed for urgent
liver transplantation, but after 24 h his LFT and clot-
ting started improving and he was taken off the trans-
plant list.
No etiological diagnosis was reached despite an ex-
haustive infectious and metabolic screening (See Table 1).
He showed no syndromic features and there was no
family history of liver involvement. He was repeatedly
investigated for mitochondrial disorders as these ALFs
can be stress-induced, without signs or symptoms of
neuromuscular disease, but liver and muscle biopsies
were first postponed, due to an upper respiratory tract
infection not associated with clotting or LFTs alterations
and then cancelled due to withdrawal of the parental
consent.
Eleven months later, aged 3.7 years, he was urgently
re-admitted with a catastrophic ALF episode after 3 days
of sore throat and untreated fever. There was multiorgan
involvement, renal dysfunction requiring dialysis and
lung complications which impaired respiratory ex-
changes. A reduced liver (segments I to IV), from a 45-
year-old small-sized deceased male donor was urgently
transplanted. He made a full recovery and he was dis-
charged on the 59th postoperative day.
The explanted liver histology showed massive pan-
lobular necrosis, coagulative central necrosis, edema-
tous portal spaces with scanty portal mononuclear and
granulocytic infiltration. Some hepatocytes were still
preserved in acinar zone 1 and showed cytoplasmic
vacuolization and degeneration. Diffuse necrosis
precluded metabolic investigations on the explanted
liver tissue. Although neurological signs were absent, a
muscle biopsy, performed 6 months after transplantation,
showed normal respiratory chain enzyme activities. Gen-
etic testing for deoxyguanosine kinase (DGUOK), DNA
polymerase γ (POLG) mutations and other genes com-
monly involved in mitochondrial DNA depletion [8–11],
showed no pathogenic mutations [7, 12, 13].
The child, now 8, shows normal growth and neurode-
velopment at his routine follow-up visits.
DNA analysis revealed compound heterozygous
pathogenic mutations in NBAS (NM_015909.3):
c.[809G > C];[2926del], p.[Gly270Ala];[Ser976Profs*16].
Both variants were absent from 7500 in-house exomes
from individuals with unrelated phenotypes and about
120,000 alleles of the Exome Aggregation Consortium
(ExAC) Server (Cambridge, MA [03/2016]). The pater-
nally inherited c.809G > C mutation affects an evolu-
tionarily highly conserved glycine and is predicted as
functionally relevant in silico (PolyPhen 2: probably
damaging (0.998); SIFT score: 0; CADD score 19.45).
The maternally inherited 1 bp deletion c.2926del causes
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a frameshift and predicts a prematurely truncated pro-
tein, missing more than 50% of wild-type polypeptide
sequences.
Discussion and conclusions
Although it is rare, pediatric ALF is a devastating event,
accounting for 10–15% of all pediatric liver transplants.
Pediatric ALF is defined as a coagulopathy, with an INR
≥1.5 not correctable by parenteral vitamin K administra-
tion, in the presence of grade III or IV hepatic encephal-
opathy (HE), or an INR ≥2.0, regardless of the presence/
absence of clinical HE, and biochemical evidence of acute
hepatocellular injury in children with no previous
evidence of liver disease [1, 2, 14]. Metabolic disorders
and viral infections are the prevalent causes of ALF in ne-
onates and infants, whilst drug-induced hepatotoxicity
and autoimmune hepatitis are more commonly identified
in older children; the etiology remains undetermined in
up to 50% of cases [2, 8–11, 14]. RALF, with complete
clinical and biochemical recovery between the critical
events, is even rarer. Reported etiologies include viruses,
autoimmune hepatitis, metabolic disorders affecting the
mitochondrial respiratory chain, the long-chain fatty acid
oxidation pathway or the carnitine cycle, dihydrolipoa-
mide dehydrogenase (E3) deficiency (OMIM: #246900)
and Wolcott-Rallison syndrome (OMIM: #226980).
Table 1 Results of the diagnostic workup
Tests Result Reference Range







Plasma aminoacidogram, acylcarnitine profile,
urinary organic acids, orotic acid, succinylacetone
and δ-aminolevulinic acid measurements
N.A.D. N.A.D




Serum transferrin isoelectrofocusing Normal profile
Ceruloplasmin 25 ng/ml >20 ng/ml
Urinary copper level 10 μg/die <40 μg/die
Autoantibody (ANA, ASMA, LKM AMA) Negative Negative
CPK 81UI/L 25–190 UI/L








(605–1230 mg/dL) (30–198 mg/dL) (45–200 mg/dL)
Lymphocyte subpopulations Normal for age Normal for age
EEG Slight diffuse cerebral
suffering during latest crisis,
otherwise normal
Normal
Brain Magnetic Resonance Imaging Normal for age Normal for age
Echocardiogram N.A.D. N.A.D.
Muscle biopsy Normal respiratory
chain enzyme activity
Normal respiratory chain enzyme activity
Renal tubular function N.A.D. N.A.D.
DGUOK/POLG sequencing No mutations
Exome sequencing Two heterozygous variant
(frameshift and missense)
in NBAS
Absent from >120.000 control alleles of the ExAC
browser an in about 7500 in-house control exomes
(Munich Exome Server)
Rx skeletal N.AD. N.A.D.
Ophthalmologic evaluation N.A.D. N.A.D.
NAD (nihil abnormal detected)
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Early identification of the cause of ALF is fundamental
as it is sometimes reversible if specific therapy is started.
While the etiological screening is carried out, supportive
treatment with restricted hydration, broad spectrum
antibiotics, antivirals and antimycotics and adequate
caloric support should be started immediately [8].
If there is a suspicion that ALF may be APAP-
induced, NAC is the elective antidote [9–11, 15],
making it crucial to ascertain whether APAP adminis-
tration may be responsible for the ALF. Yet, in some
metabolic disorders, ALF is triggered by fever and/or
viral-infection [16] and almost all patients have a
history of APAP assumption due to antipyretic treat-
ment. The recommended APAP oral dose in children
under six is 10 to 15 mg/kg/dose, with a maximum
dose of 90 mg/kg/day. A daily dose of 150 mg/kg or
higher has been reported to be hepatotoxic [17, 18]
whereas < 75 mg/kg/die has been reported to be safe
[4, 9, 18] even if anecdotic reports have suggested that
younger children may develop toxicity after repeated
therapeutic doses of APAP [9, 17, 18].
If this were the case, then NAC treatment should be
started without delay and it may still be useful 48 h after
APAP ingestion [8, 10]. Approved national triage guide-
lines for repeated supratherapeutic APAP ingestion rec-
ommend that children younger than 6 years should be
referred for emergency evaluation if they have ingested
200 mg/kg or more over a single 24-h period, 150 mg/kg
per 24-h period for the preceding 48 h, or 100 mg/kg
per 24-h period for the preceding 72 h or longer.
NAC is a thiol-group donor that assists with replenish-
ing of liver stores of glutathione (GSH), the primary
antioxidant in hepatocytes and represents the specific
antidote for paracetamol poisoning. On the efficacy of
NAC infusion in non-APAP-induced ALF, the two lar-
gest multicenter, randomized, double-blind, placebo con-
trolled studies in adults [19] and in children [20]
reached divergent conclusions. One proposed mechan-
ism of hepatocyte damage in ALF is the production of
reactive oxygen species (ROS). Upon donating an elec-
tron to unstable ROS, two GSH react together to form
glutathione disulfide. Increasing mitochondrial GSH can
be an effective strategy to prevent mitochondrial oxida-
tive stress and pro-inflammatory cytokines generation
[21]. A recent meta-analysis concluded that NAC use
for non-APAP-induced ALF is safe, it can prolong pa-
tients’ survival with native liver without transplantation,
especially in the milder grades of hepatic encephalopathy
(I or II), but it does not affect the overall survival [22].
Nonetheless, NAC infusion is part of the initial support-
ive treatment in pediatric ALF while investigations are
ongoing [8]. There is a feeling amongst operators that it
may be useful in ALF caused by other chemicals (drugs,
mushroom poisoning) [23] and there is experimental
evidence of its role in protecting mitochondria from dam-
age, even if the value of NAC use in less severe forms of
drug-induced liver injury is still being assessed [24].
The clinical presentation of this 11-month old child
was suggestive of ALF due to repeated therapeutic doses
of acetaminophen [7]. However, the child had two fur-
ther episodes of acute liver damage over a 34-month
period without having taken APAP, whilst there were no
clinical or laboratory signs of liver disease between the
episodes. Temperature was the likely triggering factor in
all three RALF episodes.
A report that mutations in the neuroblastoma ampli-
fied sequence gene (NBAS; OMIM #616483) can cause
fever-triggered recurrent liver failure (RALF) in children
was published in 2015 [16]. This mutation may also be
associated with a multisystemic phenotype of short stat-
ure, skeletal dysplasia, optic atrophy and immunological
abnormalities (Pelger-Huet), with normal motor and
cognitive development, resembling the SOPH syndrome
occurring in the Yakut population [25]. Our patient,
however, had none of these features and skeletal surveys,
bone densitometry, MRI, neurological, eye examination
and growth evaluation showed no syndromic peculiar-
ities [16, 25–28].
NBAS in zebra fish, nematodes (C.elegans) and
humans has been shown to act in concert with core fac-
tors of the nonsense-mediated mRNA decay (NMD)
pathway to co-regulate a large number of endogenous
RNA targets [29]. NMD modulates cellular stress re-
sponse pathways and membrane trafficking. Lack of
NBAS function could affect its role in NMD, its activity
as a component of the syntaxin 18 complex or com-
promise yet unreported cellular functions. Thermal sus-
ceptibility of the syntaxin 18 complex is the basis of
fever dependency of ALF episodes. Depletion of NBAS
leads to a significant upregulation of the matrix G1a
protein (MGP), responsible for bone formation. Thus,
an increased MGP activity would be compatible with the
short stature and associated bone defects in the SOPH
syndrome [25]. The phenotype and medical history of 14
individuals with NBAS deficiency showed that RALF
may present from 4 months to 6.7 years, but is not re-
stricted to childhood, and that ALF crisis, as in our case,
could be fatal without a liver transplant [28, 30]. Charac-
teristically, these patients presented with recurrent
vomiting and increasing lethargy 1 or 2 days after the
onset of fever. Syndromic SOPH-like features and
stunted linear growth have been reported in up to 77%
of the 22 children with pathological NBAS mutations
described to date, while liver cytolytic episodes, which
were absent in the original 33 SOPH cases, were present
in all 22, but did not necessarily evolve into ALF [31].
Intermediate phenotypes have recently been described
[32] Antipyretic therapy and anabolic support, including
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high glucose and parenteral lipids, effectively improve the
liver crisis [8, 16, 28, 30]. As our patient had these charac-
teristics, we tested him for a mutation in the NBAS gene,
with positive results. Not having administered APAP,
which was mistakenly considered the culprit of his liver
damage, might, in fact, have been one of the factors that
led to the catastrophic evolution of the last episode.
In conclusion, genetic defects of the energy pathways
(mitochondrial diseases have a prevalence of approxi-
mately 1 in 5000), should be part of the differential diag-
nosis in individuals presenting with ALF in isolation or
as part of a multisystemic disease presentation, especially
if drugs are involved [33].
Our case raises the suspicion that APAP assumption
at therapeutic doses, in some other reports of an associ-
ation between chronic administration of the drug and
ALF in infants with APAP levels within the normal
range on admission, may have been a red herring, lead-
ing to a hasty diagnosis and an incorrect management of
the ALF episode.
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